We are delighted to announce the IVLC which is going to be held in MUMBAI during 25Th & 26Th AUGUST, 2022. The IVLC strives to provide a meaningful theme of “BEST PRACTICES IN VACCINES” & will assemble leading specialists from around the world including researchers, scientists, academicians, vaccinologists, immunologists, healthcare professionals, clinicians, government representatives & industry delegates who will share their knowledge on the field’s most recent ground-breaking advancements & discoveries, including the front-runner COVID vaccines.
A recipient of several industry awards on Public Health, Marketing and Diversity, Mr. Navangul has also served as the Vice President of OPPI (Organisation of Pharmaceutical Producers of India) from 2014 to 2019, Chairman of AMCHAM Pharma committee (American Chamber of Commerce) from 2016 to 2019 and Chairman, Medical and Regulatory Committee from 2016 to 2019. He has been on the Academic Board of NMMIS Pharma management, IES Management school and IIHMR, Jaipur.
Bakulesh Khamar is Executive Director-R&D at Cadila Pharmaceuticals Ltd, India since 1996 and he is responsible for bringing innovations at Cadila. After obtaining his M.S. in 1980, he has been an active teacher and researcher and worked at M&J institute of ophthalmology- Ahmedabad, N.H.L. Municipal Medical College-Ahmedabad, Shankara Netralaya- Chennai and School of Optometry, Berkeley, University of California, USA. His earlier part of the carrier was restricted to eye research only. In that duration, he developed K-M Medium for corneal preservation, device for Visual activity prediction in presence of opaque media, device for visual filed screening. He also received numerous awards including Col. Rangachari Award by All India Ophthalmic society for best paper. After joining CADILA, he has started working on other areas of human health for converting knowledge in to products for healthcare interventions, key highlights are:
- Sepsivac – repurposing of an approved immunomodulator for
- Prevention of COVID-19
- Treatment of critically ill patients suffering from COVID-19
- Improving prophylactic efficacy of vaccines against SARS-CoV-2 variants
- Subunit Rabies G vaccine - world’s first subunit recombinant protein containing rabies vaccine for post exposure prophylaxis. It reduces the no. of doses to 3 from 5 needed for conventional inactivated virus containing vaccine.
- Sepsivac - world’s first immunomodulator approved for the management of gram-negative sepsis along with standard of care for reducing the morbidity and mortality
- Seasonal Influenza vaccine - first VLP vaccine for influenza.
- H1N1 Influenza vaccine - VLP vaccine for H1N1.
- Polycap - novel and world’s first polypill for prevention of cardiovascular diseases
- Mycidac-C - world’s first targeted active immunotherapy for non-small cell lung cancer.
- Intravenous (IV) Rabeprazole - first in world to raises intragastric ph. above 6.0 within 10 minutes of administration
- Risorine - novel formulation of Rifampicin with piperine, the bio enhancer
A PhD in Genetics and Plant Breeding, She did her Post Doctoral Research at The John Innes Centre, Norwich UK, Dr. Renu Swarup has been instrumental in the planning and implementation of some major National programmes. As a Science Manager issues related to policy planning and implementation were a part of her assignment. She was actively engaged in the formulation of National Biotechnology Vision and Strategy in 2001, 2007 and 2015and 2021.She was also a member of the Task Force on Women in Science constituted by the Scientific Advisory Committee to the Prime Minister.
As the Secretary of Government of India, Department of Biotechnology, she led a Network of 16 Autonomous Research Institutes, 2 Public Sector Undertaking and a R&D Network of more than 5000 projects across more than 100 research institutes, Universities and Laboratories. In the recent COVID Pandemic situation she led the COVID Vaccine ,Diagnostic and Genome sequencing Mission. The Public Sector BIRAC, for which she was the founding Managing Director and then Chairperson, has supported more than 5000 Startups and over 60 Incubators
A Fellow of the National Academy of Sciences (NASI) India, A Life Member of Trust for Advancement of Agricultural Sciences (TAAS) and a Member of the Organization for Women in Science for the Developing World (OWSD), she was awarded the “BioSpectrum Person of the Year Award” in 2012. “National Entrepreneurship Awards 2017”, TiE Award 2018, “Dr. P. Sheel Memorial Lecture Award” 2018 by NASI and the TWAS Regional Office Prize on Science Diplomacy in 2018. She has been awarded the Agriculture Research Leadership Award 2019.
Dr. Pradeep Nagalkar has over 34 years’ experience in the biotechnology industry, 21 years of his experience is in vaccine industry.
He has completed his post-graduation from Seth G. S. Medical College & K.E.M. Hospital, Parel, Mumbai. He is Ph.D. in Microbiology from University department of Chemical Technology (UDCT), Mumbai. He has Extensive knowledge of Protein purification and Biological testing. He has worked previously with National Plasma Fractionation Centre, Parel, Mumbai and Biological E., Hyderabad.
Dr. Pradeep Nagalkar is also deputed for various workshops and attended many conferences, symposiums and delivered many lecturers in national and international conferences, written scientific articles.
Lived multi-country medical “field “experience in Southeast Asia (India in particular), West/Central/East Europe and Middle East.
Speaking French, English, Italian, Russian, Czech/Slovak.
Over 10 years of experience as consultant/scientific expert and medical lead in pharmaceutical research and development for European and USA companies(Servier, Wyeth/Pfizer,Flamel technologies as global medical lead and medical director of clinical and preclinical development) within various therapeutic areas covering complex international projects.
Supporting research and cooperation around Microbiota/Immunity (certified CIMI Microbiota medical application Paris) Focus on better understanding of host immune system - pathogen-microbiota interactions for adapted intervention in transversal way including joint interest withing infectious diseases /cancer and common targets (e.g viruses/immune-oncology).
Supporting direction of Prevention and Early diagnostic (innovative biomarkers) in clinical practice and Medical care.
Member of international advisory groups (CHD India) and think tank groups in order to foster global cooperation in areas of Public health with Europe.
Speaker at various international conferences and Member of administrative boards of French academia (WAAR- antibiotic resistance, French immunology society).
Years of expertise to work globally but more focused on Asia(India in particular) and broader Eurasian cooperation as a Medical advisor bringing new innovative concepts alive and getting them endorsed.
He received Ph.D. degree in Bioanalytical/Biological Chemistry from Tohoku University (Japan), followed by postdoctoral training at University of Alabama at Birmingham (USA).
Authored 10 patents, 20+ international publications and delivered talks in National and international conferences.
His expertise includes Analytical development and characterization, conjugation of biomolecules with markers and polysaccharides including process development of biopharmaceuticals.
He has worked from R&D to tech transfer and manufacturing of different molecule. During his tenure he was involved in dealing with different regulatory agencies for approval and faced WHO, USFDA and other regulatory audits. He also actively involved with clinical research team for Preclinical and clinical trials of recombinant proteins and vaccine. He developed and commercialized many recombinant proteins, vaccines and rapid diagnostic kit.
He established the VLP technology platform for different vaccine in India in collaboration with Novavax and taken the approval for this new concept technology. He is actively involved in the development of novel therapeutic protein for cancer therapy.
He has worked with Ranbaxy, Cadila pharma, Unichem and now at present he is working as Senior Vice president at Biological E, Hyderabad.
Annu is core mass spectrometric expert with >15 years of experience in analytical method development, validation, product characterization, impurity profiling, glycan analysis. Before joining USP, she was leading the mass spectrometric applications globally for monoclonal antibodies & other biotherapeutics at SCIEX. Annu was instrumental in setting basic and advanced mass spectrometry-based workflows like glycan profiling, disulfide linkages elucidation, multi attribute methodology, native mode analysis and host cell protein analysis for therapeutic antibodies. She also has expertise in the analysis of peptides, Metabolites, Lipids, Biomarker Discovery/Verification workflows. Annu has more than 30 research papers and book chapters in peer reviewed journals. She has presented in several National and International Conferences as Invited speaker.
Served in different capacities at Indian Immunologicals Limited overseeing the process development for various Bacterial & Viral vaccines (Recombinant & Conventional), Conjugate vaccines, Monoclonal antibodies & Bio-therapeutics.
Fields of expertise include Process Development, Formulation Development – Thermostable vaccines, vaccine delivery devices and combination vaccines for Pediatric use.
Prior to joining Indian Immunologicals Limited served as Sr. General Manager, Bio Process Head at Shantha Biotechniques Limited (A Sanofi Company) and as Senior Director at MSD Wellcome Trust Hilleman Labs overseeing analytical and formulation development.
Vasan brings over 20 years of professional experience in vaccine discovery and drug development at major global corporations like Novartis, AstraZeneca, and Biocon. At these organisations he has held senior leadership positions, provided strategic directions, and orchestrated major business operations to develop affordable medicines across multiple therapeutic areas including oncology, diabetes, infectious diseases (specifically against tuberculosis and malaria) and inflammation. Most recently, he was the Chief Executive Officer at the DBT/Wellcome Trust India Alliance, a major global funding agency (annual budget of £24 million) promoting basic, biomedical and clinical research across India. He has over 50 publications in peer-reviewed international journals including Nature Medicine, Nature Immunology, Nature Communications and co-inventor on 4 patents.
Expert on strategic planning , balancing business and compliance for growth of industry.
Masters in analytical and medicinal chemistry . certified Lead auditor on quality management system and environment management from BVQI UK.
Enjoy working in diversified culture across the global geographic locations .
Expertise in handing regulatory audits, agencies communication, Acquisitions and merger processes. Quality control and assurance process.
Responsible for development of product to distribution – life cycle of product quality for uninterrupted compliant supply chain management across the organization.
She has worked for Ipca laboratories, Sun pharma , ACG group at various positions to gather expertise on quality, compliance, and strategic approach.
He is currently the CEO of stealth startup, an immunodiagnostics startup presently focused on the science of COVID-19 immunity elicited via infection or vaccination. The Startup has been involved with COVID-19 vaccine manufacturers, and academic institutions, in establishing and evaluating the cellular immunity to COVID-19. Shiv has spearheaded the establishment of various platforms at the startup that are instrumental in understanding a vaccine’s efficacy in eliciting and sustaining both T and B cell response, and further exploring how these responses are modulated under various booster dose combinations. In addition, the startup developed a simple and rapid, blood-based test that will allow one to test for T cell immunity against COVID-19 without requiring high-end research infrastructure. The test has now been used by vaccine manufacturers to screen study subjects for inclusion in, or exclusion from, a study or clinical trial. These robust and multi-faceted platforms that the startup has developed for the in-depth study of COVID-19 vaccines is easily adaptable to any disease and vaccine, depending on the need of the hour, in an accelerated timeframe.
Shiv’s previous entrepreneurial experience saw him embark on an ambitious mission to build and establish a high-end products and services entity for the UK/US-based Indoor Biotechnologies in the Asia Pacific market for immunology and allergy needs. He served as its executive director for over 6 years and during his highly successful tenure, he developed and marketed a vast portfolio of cuttingedge, innovative solutions in the areas of immunology, allergy, inflammation, immuno-oncology, and anti-viral testing. The company catered to academia and industries involved in the development of biologics, diagnostics and FMCG products.
During his career in academia, Shiv served as a Principal Investigator at the Singapore Institute for Clinical Sciences, where he built and established a new research program to probe the immunobiology of viral diseases leading to the demonstration of the seminal role of the complement system in survival following influenza infection.
Prior to this, Shiv was a recipient of the prestigious Wellcome Trust traveling and research fellowship, leading him to the School of Medicine, Cardiff University, UK, where he identified a unique and previously unknown role for CD59 in augmenting T cell immunity in infection and cancer.
Shiv has an award-winning Ph.D. in Immunology from the esteemed All India Institute of Medical Sciences (AIIMS), New Delhi.
Immediately prior to joining HLS, Dr. Ganapathy was `Head–Vaccine Development Department’ at the International Vaccine Institute (IVI), Seoul, South Korea for 3 years from May 2019. There his streamlined the technology transfer processes, vaccine process development activities, process/analytical development for new candidate vaccines, etc.; he also contributed to university education programs as `Adjunct Professor’ to Yonsei University and Seoul National University.
Before IVI Dr. Ganapathy he was with Biological E. Ltd., Hyderabad, India for over 5 years, where he helped set-up laboratories, built and led the Manufacturing Sciences team providing full-fledged support to the commercial manufacturing divisions (production & QC) -including Life-Cycle Management involving the introduction of new delivery systems, and technology transfers. Based on the work done under his leadership at BioE, an international patent involving a novel adjuvant preparation process was published.
Prior to BioE, Dr. Ganapathy worked for 2 years at Shantha Biotechnics (a Sanofi company), where he led the scale-up of the manufacturing process of a tetravalent rotavirus vaccine from Phase-I to Phase-III and oversaw the Ph-III material production and delivery. His first vaccine industry experience, however, was with Bharat Biotech International Ltd. where he worked for >14 years, and also completed his PhD through his work on a CDC-NIH-sourced multi-epitope, recombinant malarial vaccine candidate against Plasmodium falciparum. At BBIL Dr. Ganapathy spearheaded teams on projects for manufacturing vaccines for use in several clinical trials (supported by PATH/BMGF, MVI/EVI and DBT-India) and for commercial supplies. He also played a crucial role in product and process development, and in the approval of the first cell culture-derived Pandemic H1N1 Influenza vaccine in India (2009).
Dr. Ganapathy graduated as a double-gold medalist for his post-graduate work in `Medical Entomology’ from VCRC (ICMR) in 1993; and his bachelor’s degree was in `Medical Laboratory Technology’ from JIPMER (1991), both in Pondicherry, India. He has been a lead- or co-author of 11 research papers and has delivered talks at several international conferences and training programs over the last 15 years.
Recently, he has developed a commercial scale process for Linear Plasmid preparation and has been instrumental in developing the purification process for India’s first mRNA vaccine (Gemcovac) for covid-19. In the field of bioprocess development, he has received two global process patents for recombinant GCSF (US 20180223270A1) and TNK-tPA, (US20170210784A1). He has published his research work in the field of malaria and other novel drug candidates in the reputed journals. His research interest includes process development, continuous processing, manufacturing operations, process control, and technological innovations.
Arjun holds a Ph.D. in Biotechnology (SBPPU, Pune), M.Sc. in Biotechnology (DAVV, Indore) and B.Sc. in Biotechnology (Jiwaji University, Gwalior).
She is recipient of many prestigious awards; amongst them few are Bharat Bhagya Vidhata Samman 2022 and ICMR awards [Major General Saheb Singh Sockey Award, Dr. T Ramchandra Rao Award], Dr. Pran Nath Chhuttani Oration Amritsar Award, Dr Vinod Kumar Bhargava Award from (National Academy of Medical Sciences) and Dr. K.M. Bhansali Oration award, felicitated by Governor of Maharashtra , National Academy of Sciences India (NASI) as COVID warrior. She is fellow of National Academy of Agricultural sciences and member of many National and International committee including ICMR, WHO, CEPI etc.
She has published more than 270 research papers in national and international journals with very high impact factors.
At Omnibrx, he and his team are responsible for bringing the proprietary single-use bioprocessing technology, “CellBRx Bioreactor systems” to the global markets. This technology will enable the vaccine manufacturers to produce vaccines and viral vectors at large scales with ultimate process efficiency and cost effectiveness.
Currently heading Global Procurement with Stelis Biopharma, and, previously worked with various reputed companies, like Biocon Limited, Ajinomoto OmniChem, Torrent Pharma, DCM Shriram group, Nectar Lifesciences and Lupin Limited.
On the Education part, I completed an E-MBA in “Operation & Retail Management” from Nagaland Open University and “Masters in Commerce” from Kanpur University and also did a Certification Course in "Supply Chain Management", from SYMBIOSIS Centre of Distance Learning, Pune.
Dr Khalid has studied and practiced medicine in India, followed by graduate education from the University of Texas at San Antonio. He has worked in academic, non-profit and commercial entities. He has authored several publications, patents and received several grant funding from major funding agencies like EDCTP, BMGF, H2020 and CEPI. Dr Khalid has collaborated with and worked in several countries across Asia, Africa, and Europe. Dr Khalid is passionate about promoting health for all by reducing inequity in vaccine access.
Panacea Biotec group (henceforth referred as Panacea Biotec) monitors email communications sent to and from Panacea Biotec in order to protect Panacea Biotec, our employees, customers, suppliers and business partners, from cyber threats and loss of Panacea Biotec Information. Panacea Biotec monitoring is conducted with appropriate confidentiality controls and in accordance with local laws and after appropriate consultation. This email (and any attachments or links within it) may contain information that is confidential, legally privileged or otherwise protected from disclosure. The sender confirms that Panacea Biotec shall not be responsible if this email message is used for any indecent, unsolicited or illegal purposes, which are in violation of any existing laws and the sender shall at all times indemnify Panacea Biotec of any civil and/ or criminal liabilities or consequences. While Panacea Biotec has taken reasonable steps to ensure that this email and any attachments thereto are free from computer viruses and the like, it does not undertake any responsibility for loss or corruption of recipient’s data during transmission. Before opening any email, the recipient should ensure that data is free from any viruses.
She has worked in core pharma companies such as NOVARTIS, Wockhardt, AB Science (French Biopharma based in PARIS) and CRO/IT like Cognizant.
She has worked in India and Europe (Paris) and faced various regulatory inspections and worked in various therapeutic areas such as vaccine, oncology, diabetics, neurology, and generics. She has worked on postmarking and phase I to phase III drugs and supported product approvals in US, Europe and India. Shraddha is skilled in various regulatory/health agency regulations, especially USFDA, EMA, MHRA, and DCGI. Her other areas of interest are medical communications, quality assurance, regulatory requirements, audits and inspections.
Dr. Bhange earned her Bachelor of Medicine and Bachelor of Surgery (MBBS) from the Maharashtra University of Health Sciences (MUHS) under the Medical Council of India (MCI), and completed a specialized postgraduate full time program in paraclinical subjects, Msc Biomed tech from Coventry University, United Kingdom.
Key Topics for 25th August
- Indian Vaccine Industry: Present And Futuritics Approaches
- Vaccine Production & its Manufacturing
- Efficient Technology Transfers: Basic need for Vaccine R&D and Manufacturing.
- mRNA vaccine revolution
- Advances in Vaccine Analytical Methods
KEY Topics for Day 26th August
- Covid Vaccines – Present Status & Future Strategies while Preparing For Future Pandemics
- Addressing vaccine preparedness for emerging and re-emerging diseases and future outbreaks?
- Broadly protective and multi-valent vaccines and monoclonal antibodies for various bacterial and viral infections
- Logistics, last mile, and innovations to ensure successful deployment of next generation vaccines
- Connecting Human and Veterinary Vaccine Development: Looking from a One Health perspective